Implementing the NASP clinical pathway was dominant compared to no implementation, yielding an incremental gain of 0.058 QALYs and expected cost savings of JPY 59,507 per person.
Does the implementation of the NASP clinical pathway improve cost-effectiveness and QALYs in patients with acute myocardial infarction?
Implementing a standardized secondary prevention clinical pathway for intensive LDL-C management in AMI patients is a dominant strategy that improves quality-adjusted life years while reducing overall healthcare costs.
Estimación del efecto: ICER Dominant
Due to the poor prognosis associated with acute coronary syndromes (ACSs), intensive low-density lipoprotein cholesterol (LDL-C) management therapy is recommended as early as possible after the onset of ACS, with the goal of lowering plasma LDL-C to < 70 mg/dL. The purpose of this study was to evaluate the cost-effectiveness of implementing the Nagasaki Acute Myocardial Infarction Secondary Prevention Clinical Pathway (NASP) using medical records (n = 385, pre-implementation group:224, post-implementation group:161) extracted from 8 hospitals in Nagasaki.
Kurobe et al. (Mon,) conducted a other in Acute Myocardial Infarction (n=385). Nagasaki Acute Myocardial Infarction Secondary Prevention Clinical Pathway (NASP) vs. No implementation of NASP was evaluated on Incremental cost-effectiveness ratio (ICER) (ICER Dominant). Implementing the NASP clinical pathway was dominant compared to no implementation, yielding an incremental gain of 0.058 QALYs and expected cost savings of JPY 59,507 per person.